Tesamorelin is a synthetic GHRH analog that prompts the pituitary to release endogenous GH. HGH is the hormone itself. Here's what the literature says about both, why a growing community is switching from one to the other, and what to consider before you do.
Tesamorelin is a 44-amino-acid GHRH analog that signals the pituitary to release endogenous growth hormone in a pulsatile pattern matching the body's natural rhythm. HGH (somatropin) is recombinant human growth hormone delivered directly. Tesamorelin is FDA-approved for HIV-associated lipodystrophy; HGH is FDA-approved for growth hormone deficiency. Research-protocol users switch toward tesamorelin to preserve negative-feedback regulation and reduce IGF-1 spikes; the trade-off is lower peak GH levels and a different cost-per-dose profile.
The two compounds live one step apart on the same hormonal axis.
Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the pituitary to release growth hormone. The molecule is stabilized with a trans-3-hexenoic acid modification at the N-terminus that resists rapid enzymatic degradation, which is why a single subcutaneous dose can produce a sustained pituitary response despite a systemic half-life of only ~30 minutes. It is FDA-approved as Egrifta for HIV-associated lipodystrophy.
HGH in this article means recombinant human growth hormone — somatropin — produced as a 191-amino-acid protein matching endogenous GH. Brand products include Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Eli Lilly), and Saizen (Merck Serono). It is FDA-approved for growth hormone deficiency in adults and children, Turner syndrome, idiopathic short stature, and several other defined indications.
The mechanism difference matters more than the surface similarity. Tesamorelin tells the pituitary to release the body's own GH; HGH is the GH, administered exogenously. Every downstream difference in physiology, side-effect profile, and cost flows from that one structural distinction.
The pituitary releases growth hormone in pulses, not as a continuous stream. The largest pulse occurs in the first few hours of sleep, with smaller pulses through the day. This pulsatile pattern is what the GH–IGF-1 axis evolved around — receptor desensitization, downstream gene expression, and IGF-1 production are all tuned to a pulsing, not sustained, signal.
Tesamorelin preserves the pulsatile pattern. Because it acts on the pituitary GHRH receptor, the pituitary still controls the release event. Circulating IGF-1 still suppresses GHRH signaling through long-loop negative feedback. The system stays self-regulating: too much IGF-1 dampens the next pulse.
Exogenous HGH bypasses that loop. Injected somatropin produces a sustained elevation in serum GH that does not match the body's natural rhythm. The pituitary, sensing elevated IGF-1 from the exogenous signal, downregulates its own GH output. With long-term HGH use, the endogenous pulse can become suppressed and slow to recover after cessation.
The IGF-1 dynamics follow from this. Tesamorelin protocols produce a modest IGF-1 elevation that stays within or near the physiologic range at standard doses. Exogenous HGH at clinical doses produces a more pronounced IGF-1 elevation, and supraphysiologic protocols push IGF-1 well above the reference range — which is mechanistically tied to several of the long-term HGH side-effect categories.
Tesamorelin. The pivotal trial is Falutz et al., New England Journal of Medicine, 2007 — a 26-week randomized placebo-controlled study in 412 HIV-infected adults with abdominal lipohypertrophy. The 2 mg/day tesamorelin arm produced a mean 15.2% reduction in visceral adipose tissue versus placebo, with corresponding improvements in triglycerides and IGF-1 normalization to the upper-normal range. A 26-week extension confirmed durability of the effect. Side effects were predominantly injection-site reactions, arthralgia, peripheral edema, and mild glucose-tolerance shifts. No malignancy signal emerged.
HGH. The somatropin literature is decades older and broader. The defining adult-GH-deficiency trials in the 1990s established that 0.15–0.30 mg/day somatropin restores IGF-1 to the age-appropriate range and improves body composition, lipid profile, and quality-of-life measures. Side-effect profile across multiple trials: fluid retention, arthralgia, carpal tunnel syndrome, and increased fasting insulin — the last of which is the durable concern in long-term use. The clinical-dose IGF-1 elevation is larger than what tesamorelin produces at its approved dose.
The literatures are not directly comparable because the indications are different (lipodystrophy vs growth hormone deficiency) and the endpoints differ. What is comparable is the structural pattern: tesamorelin produces smaller, more physiologic effects; HGH produces larger, more pronounced effects, with a heavier side-effect tail.
The audited research-peptide pricing index covers tesamorelin from multiple vendors. Per-mg pricing as of the May 2026 peptides-index snapshot:
| Vendor | Vial size | Price | Per mg |
|---|---|---|---|
| Prime Research Peptides | 50 mg | $260 | $5.20 |
| Prime Research Peptides | 40 mg | $220 | $5.50 |
| Prime Research Peptides | 30 mg | $180 | $6.00 |
| BioTech Peptides | 10 mg | $73 | $7.30 |
| BioTech Peptides | 5 mg | $38 | $7.60 |
| Ascension Peptides | 5 mg | $85 | $17.00 |
| Swiss Chems | 2 mg | $27.95 | $13.97 |
At the 2 mg/day research protocol, the cheapest catalog tier lands around $10/day in compound cost; the most expensive single-vial tier sits closer to $35/day. A 30-day protocol therefore runs $300–$1,050 at the research-peptide channel.
HGH pricing is harder to pin down. Brand pharmacy prices for adult-GH-deficiency doses (Genotropin, Norditropin, Humatrope) typically run $1,000–$3,000+ per month through standard prescription channels, with significant variation by insurance and pharmacy. Compounded HGH from 503A pharmacies and grey-market sources does not publish per-IU pricing in any structured way that maps to a verifiable index. The dollar comparison is therefore structurally lopsided: tesamorelin per-mg pricing is transparent and competitive; HGH pricing is opaque outside the brand-pharmacy channel and significantly higher when transparent.
The r/Peptides thread "anybody switch to GH secretagogues after years on HGH" drew 47 comments — long-term HGH users walking through their reasons for moving toward tesamorelin or other GH-axis compounds. The pattern in the responses tracks the mechanism difference.
The recurring reasons cited by people who switched: concern about long-term pituitary suppression, IGF-1 elevations approaching or exceeding the reference range on HGH protocols, the cost gap once tesamorelin entered the research-peptide channel at sub-$10/mg pricing, and a preference for the pulsatile mechanism on a "system stays self-regulating" basis. None of these are clinical-trial endpoints; they are reasons people give for the switch.
The trend is real enough to show up in search volume — "tesamorelin vs hgh" hit 260 monthly searches with a 433% year-over-year increase per the SEO research that informed this article. The compounds are mechanistically different but they sit in the same axis, and the GH-secretagogue alternatives (tesamorelin, ipamorelin, MK-677, CJC-1295) have all gained search interest as the HGH conversation has matured.
Three structural considerations the literature supports:
HPA axis recovery time. After long-term exogenous HGH use, the endogenous pulse can take weeks to months to recover. There is no published clinical guideline for this transition because it is not a recognized clinical protocol; the rate of recovery varies and is not characterized in controlled studies. The mechanistic expectation is that the longer the HGH suppression, the slower the GHRH-driven pulse returns.
IGF-1 monitoring. Both compounds modulate IGF-1, and any GH-axis protocol benefits from baseline and follow-up IGF-1 measurement. A switch protocol should establish where IGF-1 sits before the change and re-test after the transition window. The reference range is age-dependent.
Indication mismatch. Tesamorelin is FDA-approved for HIV lipodystrophy; HGH is FDA-approved for growth hormone deficiency. Neither is approved for general body recomposition, anti-aging, or athletic performance. Research-protocol use sits outside the approved indications by definition and outside the legal prescription channel except in narrow medical contexts.
Three gaps a careful reader should hold:
These are real gaps. They are also the dimensions on which the community discussion runs ahead of the published evidence.
Tesamorelin is a synthetic 44-amino-acid analog of growth-hormone-releasing hormone (GHRH). It binds the GHRH receptor on pituitary somatotrophs and prompts the pituitary to release the body's own growth hormone in pulses. HGH (recombinant human growth hormone, somatropin) is the hormone itself, administered directly. Tesamorelin acts upstream of GH; HGH bypasses the pituitary entirely.
The reported reasons cluster around three points. First, tesamorelin preserves the GH–IGF-1 negative-feedback loop — the pituitary still responds to circulating IGF-1, which keeps the system self-regulating. Second, the pulsatile release pattern is closer to the body's natural overnight GH rhythm than the sustained levels produced by exogenous somatropin. Third, long-term users report concern about pituitary suppression and want to recover endogenous signaling. The trade-off is lower peak GH and IGF-1 levels at any given dose.
Research-grade tesamorelin in the audited vendor catalog runs roughly $5.20–$17.00 per mg depending on vial size, with the typical 2 mg/day research protocol landing around $10–$25 per day at the cheaper end. Recombinant HGH is sold in IU rather than mg and the legal pharmacy price (Genotropin, Norditropin, Humatrope) typically runs $1,000–$3,000+ per month at clinical doses. Compounded HGH pricing is opaque and not published openly. The per-mg comparison is structurally lopsided.
Yes. Tesamorelin side effects in the Falutz et al. NEJM 2007 lipodystrophy trial were predominantly injection-site reactions and arthralgia, with edema and hyperglycemia at lower frequencies. HGH side effects include carpal tunnel syndrome, peripheral edema, and insulin resistance — these scale with the magnitude of the IGF-1 elevation, which is higher with exogenous HGH at clinical doses. The pulsatile-versus-sustained difference is the structural reason the side-effect profiles diverge.
The combination is not characterized in peer-reviewed clinical trial data. Mechanistically, adding exogenous HGH to a tesamorelin protocol would suppress the GHRH-driven endogenous pulse via negative feedback — defeating the structural reason most users choose tesamorelin in the first place. The literature does not support a combined protocol, and no published study reports a coherent stacking rationale.
Yes — tesamorelin is FDA-approved as Egrifta (2010) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It is not approved for general weight loss, anti-aging, body recomposition, or athletic performance. Research-grade tesamorelin sold by peptide vendors is the same molecule but is not pharmaceutical-grade and is sold for research use only.
New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.